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Abstract: Objective: In a recent genome-wide association study of subcortical brain volumes,1
we have identified common genetic variation at rs945270 as having the strongest
effect on putamen volume, a brain measure linked to familial risk for attention-
deficit/hyperactivity disorder (ADHD). To determine whether rs945270 is a genetic
determinant of ADHD, we now explored it impacts on ADHD-related symptoms and on
neural mechanisms of ADHD, such as response inhibition and reward sensitivity.
Method: We used a large population sample of 1,834 14-years old adolescents to test
the effects of rs945270 on (i) ADHD symptoms accessed through the Strengths and
Difficulties Questionnaire (SDQ) and (ii) Region-of-interest (ROI) analyses of putamen
activation by functional magnetic resonance imaging (fMRI) using the Stop Signal
(SST) and monetary incentive delay (MID) tasks, assessing response inhibition and
rewards sensitivity, respectively.
Results: We found a significant link between rs945270 and ADHD symptoms scores,
the C-allele being associated with lower symptoms scores, most notably hyperactivity.
We also observed sex-specific effects of this variant on the brain. In boys, the C-allele
associated with lower putamen activity during successful response inhibition, a brain
response that was not associated with ADHD symptoms. In girls, putamen activation
during reward anticipation increased with the number of C-alleles, most significantly in
the right putamen. Remarkably, right putamen activation during reward anticipation
tended to negatively correlate with ADHD symptoms.
Conclusions: Our results indicate that rs945270 may contribute to the genetic risk of
ADHD partly through its effects on hyperactivity and reward processing in girls.
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ABSTRACT 
Objective: In a recent genome-wide association study of subcortical brain volumes, we 
identified common genetic variation at rs945270 as having the strongest effect on putamen 
volume, a brain measure linked to familial risk for attention-deficit/hyperactivity disorder 
(ADHD). To determine whether rs945270 is a genetic determinant of ADHD, we now 
explore its impacts on ADHD-related symptoms and neural mechanisms of ADHD, such as 
response inhibition and reward sensitivity.  
Method: We used a large population sample of 1,834 14-year-old adolescents to test the 
effects of rs945270 on (i) ADHD symptoms accessed through the Strengths and Difficulties 
Questionnaire (SDQ) and (ii) region-of-interest (ROI) analyses of putamen activation by 
functional magnetic resonance imaging (fMRI) using the stop signal (SST) and monetary 
incentive delay (MID) tasks, assessing response inhibition and reward sensitivity, 
respectively.  
Results: We found a significant link between rs945270 and ADHD symptom scores, with the 
C-allele associated with lower symptom scores, most notably hyperactivity. We also observed 
sex-specific effects of this variant on the brain. In boys, the C-allele was associated with lower 
putamen activity during successful response inhibition, a brain response that was not 
associated with ADHD symptoms. In girls, putamen activation during reward anticipation 
increased with the number of C-alleles, most significantly in the right putamen. Remarkably, 
right putamen activation during reward anticipation tended to negatively correlate with ADHD 
symptoms. 
Blinded Manuscript - No Author Information
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Conclusion: Our results indicate that rs945270 may contribute to the genetic risk of ADHD 
partly through its effects on hyperactivity and reward processing in girls. 
Key words: rs945270, putamen, ADHD, reward anticipation, response control. 
INTRODUCTION 
Abnormalities in subcortical brain structures, notably in the putamen,1,2 have been linked 
to attention-deficit/hyperactivity disorder (ADHD), a highly heritable and multifactorial 
neurodevelopmental disorder characterized by symptoms of inattention and 
hyperactivity/impulsivity.3 The age-dependent reductions in putamen volume that normally 
occur during childhood throughout early adulthood are not observed in patients with ADHD 
and their non-affected siblings,4,5 suggesting that heritable differences in developmental 
putamen trajectories contribute to the risk for ADHD. Thus, the examination of individual 
differences in ADHD-related measures including the putamen in a nonclinical sample of 
youth may provide valuable insight into the disease. 
That abnormalities within the putamen contribute to the pathology of ADHD is further 
supported by findings showing that lesions of the putamen tend to be associated with ADHD 
symptomatology.6,7 Functional neuroimaging approaches have been helpful in identifying the 
neural mechanisms underlying ADHD symptoms. Task-based functional magnetic resonance 
imaging (fMRI) studies have shown that ADHD associates with poor response inhibition (i.e., 
a deficit in the ability to stop an already planned or initiated action), due to abnormalities in 
frontal-striatal and frontal-parietal networks in adolescents and young adults with ADHD,8-10 
which may underlie some of the deficits in impulse control observed in ADHD.11 On the other 
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hand, several fMRI studies have observed decreased activation of the ventral striatum, an area 
including the ventromedial putamen,12 during anticipation of reward in both adolescents and 
adults with ADHD, which led to the hypothesis that ADHD is part of a reward deficiency 
syndrome reflecting the impact of dysregulation of dopamine on the reward system.13,14 
Despite evidence implicating the putamen in the pathology of ADHD, its distinctive 
contributions in the neurobiology of ADHD remains understudied, possibly because small 
subcortical brain regions like the putamen are relatively difficult to observe in whole-brain 
fMRI.  
  Progress to identify genetic factors contributing to putamen development was made through 
our recent genome-wide meta-analysis that identified several single nucleotide polymorphisms 
(SNPs) associating with subcortical regions, with the strongest effects observed for rs94527 on 
the volume of the putamen. Genotypes at this SNP appear to have functional consequences, as 
the C-allele at this locus, which associates with increased putamen volume, also associates 
with increased expression of the nearby KTN1 gene in the brain and in blood.15 This gene is 
known to play a role in intracellular organelle motility, and it is interesting to note that its 
expression was found to be decreased in patients with Parkinson's disease16 and in women with 
depression undergoing antidepressant treatment.17 Results of these analyses also indicated that 
while rs945270 associated with putamen volume across the lifespan, the effects of this SNP on 
putamen volume tended to decrease with the mean age of each participating cohort.15 This, and 
the age-dependent reductions of putamen volume from childhood through early adulthood in 
controls but not in individuals with ADHD or their unaffected siblings,5 suggested that 
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rs945270’s effect on the putamen might predispose to ADHD. 
 To test this, we analyzed the effects of rs945270 on putamen function and its relation to 
ADHD-related phenotypes in a large healthy cohort of 14-year-old adolescents, using the 
stop-signal (SST) and the monetary incentive delay (MID) fMRI tasks that assess motor 
control and reward processing, respectively.  
METHOD 
Participants 
Participants of the study were tested at eight assessment centers (London, Nottingham, 
Dublin, Mannheim, Berlin, Hamburg, Paris, and Dresden). Local ethics research committees 
at each site approved the study. On the day of assessment, written consent was obtained from 
the parent or guardian, and verbal assent was obtained from the adolescent. A detailed 
description of the recruitment and assessment procedures and inclusion/exclusion criteria 
have been published elsewhere.18 After quality control, complete and reliable datasets were 
available from 1,129 participants during the reward anticipation phase of the monetary 
incentive delay task (MID), and from 1,227 participants for the successful inhibition in the 
stop signal task (SST). Demographics information is displayed in Table 1.  
ADHD Symptoms (Strength and Difficulties Questionnaire) 
ADHD symptoms were assessed using parental reports of the Strength and Difficulties 
Questionnaire (SDQ), a 25-item behavioral screening tool probing for ADHD-type problems 
(hyperactivity, inattention, and impulsivity), emotional symptoms, conduct problems, peer 
problems, and prosocial behavior.19 For this study, we used the SDQ ADHD symptoms scale, 
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which provides a sum score (ranging from 0 to 10) for both hyperactivity/impulsivity (with a 
3-item subscale, with scores ranging from 0 to 6) and inattention (with a 2-item subscale, 
scores ranging from 0 to 4). The Development and Well-Being Assessment (DAWBA)20 was 
also used to administer a structured interview to parents and children, which was used by 
experienced clinical raters to assign DSM-IV diagnoses blind to the SDQ scores. 
Genotyping and Quality Control 
DNA purification and genotyping was performed by the Centre National de Génotypage 
in Paris. DNA was extracted from whole blood samples preserved in 
ethylene-diamine-tetra-acetic acid (EDTA) vacutainer tubes (BD, Becton, Dickinson and 
Company, Oxford, UK) using the Gentra Puregene Blood Kit (QIAGEN, Valencia, CA) 
according to the manufacturer’s instructions. Genotype information was collected at 582,982 
markers using the Illumina HumanHap610 Genotyping BeadChip (Illumina, San Diego, 
CA).18 A total of 705 and 1,382 individuals were genotyped with the Illumina (Little 
Chesterford, UK) Human610-Quad Beadchip and Illumina Human660-Quad Beadchip, 
respectively. SNPs with call rates <98%, minor allele frequency <1%, or deviation from the 
Hardy–Weinberg equilibrium (P <1 × 10−4) were excluded from analyses. Individuals with an 
ambiguous sex code, excessive missing genotypes (failure rate >2%), and outlying 
heterozygosity (heterozygosity rate of 3 SDs from the mean) were also excluded. Identity by 
state similarity was used to estimate cryptic relatedness for each pair of individuals using the 
PLINK software (pngu.mgh.harvard.edu/∼purcell/plink/). Closely related individuals with 
identity by descent >0.1875 were eliminated from the subsequent analysis. Population 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
6  
 
stratification for the genome-wide association study (GWAS) was examined using 
multidimensional scaling (MDS) analysis with HapMap populations as reference groups. 
Individuals with divergent ancestry (from Utah residents with ancestry from northern and 
western Europe) were excluded through visual inspection of the first two components. Figure 
S1 (available online) shows that our sample is genetically homogeneous (overlapping with 
the Utah residents with northern and western ancestry [CEU] population). The imputation 
protocol used MaCH software for haplotype phasing and minimac for imputation.21  
MRI Data Acquisition and Preprocessing 
MRI data were acquired with 3T MRI scanners of different manufacturers (Siemens, 
Munich, Germany; Philips, Best, The Netherlands; General Electric, Chalfont St Giles, UK; 
Bruker, Ettlingen, Germany) using the same scanning protocol at all sites (see supplemental 
material, available online). High-resolution T1-weighted 3D structural images were acquired 
for anatomical localization and coregistration with the functional time series. Forty slices, 
tilted to the anterior-posterior commissure line, were acquired in descending order (2.4 mm 
thickness, 1 mm gap) using a gradient-echo T2*-weighted echo-planar imaging (EPI) 
sequence, and the following parameters: TR = 2200 ms; TE = 30 ms; matrix size 64 × 64 
over a 21.8-cm field of view, giving an in-plane resolution voxel size of 3.4 × 3.4 mm. For 
anatomical reference, a 3D gradient echo-based sequence of the whole brain was obtained, 
using protocol based on the Alzheimer's Disease Neuroimaging Initiative (ADNI) protocol 
(http://www.loni.ucla.edu/ADNI/Cores/index.shtml). 
  fMRI data were analyzed with SPM8 (Statistical Parametric Mapping, 
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http://www.fil.ion.ucl.ac.uk/spm). Spatial preprocessing included: slice time correction to 
adjust for time differences due to multi-slice imaging acquisition, realignment to the first 
volume in line, non-linearly warping to the Montreal Neurological Institute (MNI) space 
(based on a custom EPI template [53x63x46 voxels] created out of an average of the mean 
images of 200 adolescents), resampling at a resolution of 3x3x3mm3 and smoothing with an 
isotropic Gaussian kernel of 5 mm full width at half maximum. At the first level of analysis, 
changes in the blood oxygen level-dependent (BOLD) response for each participant were 
assessed by linear combinations at the individual participant level; for each experimental 
condition, each trial (e.g., anticipation of high gain in the MID task) was convolved with the 
hemodynamic response function to form regressors that account for potential noise variance, 
e.g. head movement. Estimated movement parameters were added to the design matrix in the 
form of 18 additional columns (3 translations, 3 rotations, 3 quadratic and 3 cubic translations, 
and each 3 translations with a shift of ±1 TR). 
  We extracted the putamen ROI using the Marsbar toolbox (http://marsbar.sourceforge.net), 
based on the MNI Automated Anatomical Labeling. Averaged beta values based on all voxels 
in the left and right putamen were used for ROI analyses. The current study used the contrast 
successful stop vs. successful go trials to access brain activity associated with inhibition of a 
motor response in the SST. For the MID task, we used the contrast anticipation of high win vs. 
anticipation of no win based on prior research suggesting reliable associations between 
ADHD symptoms and fMRI BOLD responses measured during reward anticipation.22 
Monetary Incentive Delay Task 
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To examine neural responses to reward anticipation and outcome, participants performed 
an age-adapted version of the monetary incentive delay (MID) task23 in which sweets instead 
of money were used as reward. It is a reaction time task that assesses how quickly the 
participant presses a button with left or right index finger to hit a target (white square) that 
only appears for a short time on the left or right side of the screen.   
Stop Signal Task 
The stop signal task (SST) was used to study neural responses to successful and 
unsuccessful inhibitory control.24 Participants were instructed to make a single, button-press 
response to either of two regularly presented, visual-go stimuli (arrows pointing left or right 
shown centrally for 1000 ms), unless followed by an unpredictable stop signal (arrow 
pointing upwards shown for 100–300 ms). Twenty percent of the go stimuli were followed by 
a stop signal. The dependent variable of the task is the stop signal reaction time (SSRT), 
which was calculated by subtracting the mean stop signal delay (the average time between go 
and stop signal, where the participant managed to inhibit 50% of trials) from the mean 
reaction time to go trials.25 Because of problems in the tracking algorithm, SSRT data was 
only available for half of participants (see supplemental material, available online). 
Participants had first completed a practice session outside the scanner (for ~5 minutes).  
Statistical Analyses 
The general linear model was used to calculate associations between ADHD symptom 
scores, BOLD responses, behavioral measures and genotype, controlling for covariates of sex 
(depending on the analyses), scanning sites (7 dummy variables), and handedness. All analyses 
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were two-sided. Since those hypotheses for brain activity involved the two hemispheres and 
two contrasts, the significance threshold was set to 0.0125 using Bonferroni correction. 
To investigate the stability of our main findings, we have carried out two internal 
replications. First, we tested the same association in eight research sites separately. The 
regression coefficients (𝛽) and their corresponding standard errors (SEs) were then used to 
conduct a meta-analysis. The R package rmeta 
(https://cran.r-project.org/web/packages/rmeta/ rmeta.pdf) was then used to generate the 
forest plot. Second, a resampling of the original data with replacement (a bootstrapping 
process) was conducted to generate a new sample with the same sample size as the original 
data. The process was replicated 10,000 times, and all of the t statistics were used to calculate 
a bootstrapping p-value. By these two replications, we demonstrated both the stability of the 
results and the fact that they are unlikely to reflect sample-specific variance. 
RESULTS 
Relationship of rs945270 With ADHD Symptoms 
In our population cohort of 14-year-old adolescents, each copy of the C allele was 
associated with a 77.4 mm3 increase in the averaged volume of the bilateral putamen (𝛽 = 77.4, 
1.1% variance explained, p = 1.3 x 10-5). While we noted a sex difference for putamen volume 
(smaller volume in girls than in boys: 𝛽= -554.5, p < 10-10), there was no interaction between 
sex and genotype at rs945270 on putamen volume (𝛽 = -16.1, p = .65). Investigating the 
relationship between rs945270 and ADHD symptoms, we found that rs945270 significantly 
associated with ADHD symptoms in the full sample. The C-allele at rs945270 associated with 
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lower scores for ADHD symptoms compared to the G-allele, such that each C-allele is 
expected to reduce symptoms scores by 0.067 SD (𝛽 = -0.21, 𝛽stand = 0.067, p = .0053; 
bootstrapping:  p = .0070; meta-analysis: 𝛽 = -0.21, p = .0063; Figure 1 and Table 2). Testing 
for the specificity of rs945270 on ADHD symptoms, we found that variation at rs945270 was 
mostly associated with hyperactivity symptoms (𝛽 = -0.126, 𝛽stand = -0.065, p = .0054 and 𝛽 
= -0.093, 𝛽stand = -0.051, p = .028 for the hyperactivity and inattention subscales, respectively). 
Testing for possible sex differences in ADHD symptoms, we found that girls scored lower for 
ADHD symptoms than boys (𝛽 = -0.77, 𝛽stand = -0.169, p = 1.12 x 10-12), differing relatively 
more in inattentive (𝛽 = -0.406, 𝛽stand = -0.162, p = 6.77 x 10-12) than in hyperactive (𝛽 = 
-0.361, 𝛽stand = -0.134, p = 1.37 x 10-8) symptoms. There was no sex-by- rs945270 genotype 
interaction on ADHD symptoms (𝛽 = 0.049, p = .71). ADHD symptom scores were not 
associated with putamen volume in this sample (𝛽 = -0.00012, p = .28); the association 
between rs945270 genotypes and ADHD symptoms remained significant after controlling for 
the whole putamen volume. 
Testing for the specificity of rs945270 effects, we analyzed its association with the other 
four symptom domains measured by the SDQ. We found nominal association of rs945270 with 
the emotional symptoms score (𝛽 = -0.15, p = .021), not with the conduct (𝛽 = -0.048, p = .37), 
peer problem (𝛽 = -0.074, p = .17), and prosocial (𝛽 = 0.075, p = .21) scores.  
As about 2.5% of our sample had received a diagnosis of ADHD (11 girls and 35 boys), 
based on the DAWBA,20 we tested how well the SDQ symptom scores correlated with the 
ADHD diagnosis. There was a moderate positive correlation ( = 0.304, p = 4.23 x10-40) 
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between the two variables, confirming the utility of the SDQ as a screening tool for ADHD in 
the community.26 
Response Inhibition 
We next tested the effects of rs945270 on inhibitory control, assessing BOLD responses in 
the putamen during successful inhibition of motor response in the SST fMRI task. The C-allele 
of rs945270 associated with decreased putamen activity (left putamen: 𝛽 = -0.088, p = .0030; 
bootstrapping p = .0060; meta-analysis, 𝛽 = -0.080, p = .0039; right putamen: 𝛽 = -0.089, p 
= .0018, bootstrapping p = .0020; meta-analysis, 𝛽 = -0.094, p = .0016) in the full sample 
(Table 3). Girls had lower BOLD responses than boys, most significantly in the left putamen 
(left: 𝛽 = -0.15, p = .002; right: 𝛽 = -0.084, p = .035), and we observed a significant 
sex-by-genotype interaction in the left (𝛽  = 0.16, p = .0080; bootstrapping p = .0080; 
meta-analysis 𝛽 = 0.17, p = .013), but not in the right putamen (𝛽 = 0.087, p = .12) (Table 3). 
Sex-specific analyses indicated that the associations of rs945270 with putamen activity 
observed in the full sample were mainly driven by boys; the C-allele was associated with 
decreased putamen activation in this group (left putamen: 𝛽 = -0.16, p = .0005; right putamen: 
𝛽 = -0.13, p = .004), but not in girls (left putamen: 𝛽 = -0.010, p = .78; right putamen: 𝛽 = 
-0.047, p = .20) (Figure 2A, B). To test if these effects of rs945270 on putamen activation in 
boys were localized rather that distributed throughout the whole putamen, we performed post 
hoc, voxel-wise association within the putamen. These revealed significant clusters of activity 
only in the right putamen, in caudal regions (Figure S2, Table S1, available online). This 
suggests that rs945270 influences response inhibition in boys throughout global rather than 
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localized effects on the left putamen. Although we observed significant negative association 
between putamen volume and left putamen activation in the full sample (left: 𝛽 = -0.000093, p 
= .018, right: 𝛽  = -0.000063, p = .12), the association between genotype and putamen 
activation remained significant after controlling for putamen volume. However, while 
rs945270 variation associated with putamen activation during successful inhibition in boys, we 
found no significant association between putamen activation and ADHD symptoms, neither in 
the full sample (Table 3) nor when analyzing boys only (left: 𝛽 = 0.16, p = .19, right: 𝛽 = 0.10, 
p = .43). This indicates differences in putamen activation during successful inhibition are 
unlikely to account for the association between rs945270 and ADHD symptoms noted above. 
To test if these differences in putamen activation were reflected at the behavioral level, 
we analyzed a subsample of n = 671 individuals with information on duration of the stop 
process (SSRT), a known proxy for ADHD symptoms that also correlated with ADHD 
symptom scores in our sample (𝛽 = 1.44, p = .014). Putamen activation during successful 
stopping negatively correlated with SSRT in the full sample (left: 𝛽 = -12.28, p = 2.50 x 10-8, 
right: 𝛽 = -11.83, p = 1.0x 10-6), so that individuals who stopped their responses more quickly 
activated this region more strongly. While there were no sex differences for SSRT (𝛽 = -1.532, 
p = .68), an interaction between sex and left putamen activation on SSRT (p = .009) was 
observed. Left putamen activation during response inhibition negatively correlated with SSRT 
in boys, not in girls (boys: 𝛽 = -16.97, , 𝛽stand = -0.309, p = 10-10; girls: 𝛽 = -5.52, 𝛽stand = 
-0.112, p = .090).  
Reward Anticipation 
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In the fMRI reward anticipation task, we observed lesser activation in the putamen 
bilaterally in girls compared to boys (left: 𝛽 = -0.10, p = 5 x 10-6; right: 𝛽 = -0.090, p = 3.9 x 
10-5). No significant main effect of rs945270 genotype on putamen activation was observed 
(𝛽 = 0.016, p = .66 and 𝛽 = 0.022, p = .38, for the left and right putamen, respectively). 
However, there was a significant sex-by-genotype interaction for activation in the right 
putamen (𝛽 = 0.084, p = .0065; bootstrapping p = .011; meta-analysis, 𝛽 = 0.065, p = .0044; 
Left putamen: 𝛽  = 0.054, p = .086; Figure 3A, B). Sex-specific analyses indicated that 
putamen activation increased with the number of C-alleles at rs945270 in girls, most 
significantly in the right putamen (left: 𝛽 = 0.045, p = .035; right: 𝛽 = 0.066, p = .002). We 
performed post hoc voxel-wise association analysis within the putamen to test if these effects 
of rs945270 on right putamen activation in girls were due to localized effects of rs945270 in 
the putamen. These identified significant clusters in the right anterior ventral putamen 
associating with rs945270 (Figure S3, Table S2, available online). This indicates that 
rs945270 influences reward sensitivity in girls through localized effects on the right putamen. 
Analyses in boys did not reveal genotype differences (left: 𝛽= -0.009, p = .71, right: 𝛽 = 
-0.019, p = .4). There were significant associations between putamen volume and putamen 
activation in this task (left: 𝛽 = 0.000085, p = .000041, right: 𝛽 = 0.000078, p = .00023), 
which were driven by girls (left: 𝛽 = 0.00012, p = .000016, right: 𝛽 = 0.00011, p = .00007), 
not by boys. Besides, the associations between genotype and putamen activation remained 
significant after controlling for putamen volume. 
Given the reported decrease in ventral striatal activation during anticipation of reward in 
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both adolescents and adults with ADHD,27-30 we investigated this link further in our sample. 
We found significant negative association between right putamen activation during reward 
anticipation and ADHD symptom scores in the full sample (left: 𝛽 = -0.009, p = .089, right: 
𝛽 = -0.012, p = .014). We found a negative trend for association between right putamen 
activation during reward anticipation and ADHD symptoms in the full sample (left: 𝛽 = 
-0.009, p = .089, right: 𝛽 = -0.012, p = .014), reflecting an association with hyperactivity 
rather than inattention (Table 3). This suggests that the G-allele at rs945270 may partly 
contribute to the risk of ADHD through its negative effects on reward processing and positive 
effect on hyperactivity, particularly in girls. 
DISCUSSION 
Our study provides the first genetic link between putamen structure and function and risk 
for ADHD. We demonstrate that the rs945270 variant, identified in a previous genome-wide 
meta-analysis of putamen volume, associates with ADHD symptom scores at age 14 years, 
notably with hyperactivity. We also found it may contribute to the genetic risk of ADHD by 
influencing neural mechanisms in a sex-specific manner. Specifically, the G-allele at this 
locus may partly contribute to the risk of ADHD in girls through its negative effects on reward 
processing in the right anterior ventral putamen and positive effect on hyperactivity. We also 
found that rs945270 genotypes affected putamen activation during successful response 
inhibition in boys, an effect that did not correlate with ADHD symptoms.  
  Our findings that a genetic polymorphism influences neural mechanisms related to ADHD 
(i.e., reward sensitivity) confirms previous evidence suggesting that a common set of genes 
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may contribute to the distinct symptoms of ADHD.31 They also considerably extend these 
conclusions by providing a genetic mechanism that clarifies sexually dimorphic phenomena 
associated with ADHD.32 Sexual dimorphisms were evident during both response inhibition 
and reward anticipation, the putamen being activated to a lesser extent in girls compared to 
boys. The G-allele at rs945270 not only associated with higher scores of ADHD symptoms; it 
also accentuated sexually dimorphic responses by increasing putamen activity during 
response inhibition in boys and decreasing that in girls during reward anticipation. That girl 
carriers of the risk G-allele at rs945270 exhibit significantly lowered putamen activation 
compared to carriers of the C-allele when anticipating a reward suggests that this locus 
influences reward sensitivity in girls. The negative correlation between BOLD responses in 
the right putamen during reward anticipation and ADHD symptoms is indeed consistent with 
a blunted reward system,29 as evidenced by hypo-responsiveness of the ventral striatum (VS) 
in patients with ADHD.27, 28, 33, 34  
Our voxel-wise analyses showing specific effects of rs945270 on the anterior and the 
posterior putamen in the reward- and motor response-related tasks respectively provide further 
support for earlier reports of putamen segmentation35-38 indicating gradual functional 
specialization within the putamen. Rostral subregions are important for goal-direct behaviors, 
motivation, and emotional processing, and higher-order cognitive aspects of motor function, 
such as learning new movements, through connections to the anterior cingulate cortex, 
presupplementary motor area, and prefrontal cortex.39 In contrast, more caudal regions are 
implicated in planning and execution of well-learned, skilled movements, through connections 
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to primary and supplementary motor cortices.39,40 A major implication of our study is that 
genes may impact these putamen-related functions differently in men and women. 
 Our use of parental reports for the SDQ has a number of limitations. The SDQ has 
demonstrated reasonable efficiency in screening for ADHD in the community,26 and it is 
notable that its hyperactivity/inattention scale performs similarly to the “any disorder” scale 
despite its brevity. However, this screening efficiency depends on the informant, with the 
combination of parent and teacher reports being a better predictor of ADHD. Thus, our use of 
single informant limited our ability to detect ADHD symptoms. It has also limited our ability to 
properly measure the impact of emotional disorders, which are better captured by self-reports. 
These limitations are further exacerbated by the poor ability of the SDQ to identify other 
disorders such as specific phobias, panic disorder/agoraphobia, eating disorders, and 
separation anxiety. Thus, comorbidity and other unmeasured covariates, such as 
socioeconomic status, parental psychopathology, and life events could have contributed to our 
findings. 
Nonetheless, our findings illustrate the sex-dependant impact of a genetic variation on 
human brain function and potential implications for ADHD. Further studies of patients and 
their controls, taking the above limitations into account, are needed to determine if rs945270 
can help the detection and classification of ADHD and its subtypes and disease outcome. 
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Table 1: Demographics Split by Tasks (Monetary Incentive Delay and Stop Signal) and Sex  
Reward Anticipation Successful Inhibition 
 Boys  
(n = 543) 
Girls 
 (n = 586) 
Boys  
(n = 577) 
Girls 
 (n = 650) 
Age (in years) 14.4 ± 0.4 14.4 ± 0.4 14.4 ± 0.4 14.4 ± 0.4 
Handedness 84 L/A 
459 R  
62 L/A 
524 R 
78 L/A 
499 R 
62 L/A 
588 R 
rs945270 
genotypes 
GG: 103 
GC: 229 
CC: 211 
GG: 97 
GC: 302 
CC: 187 
GG: 107 
GC: 267 
CC: 203 
GG: 106 
GC: 336 
CC: 208 
ADHD 
symptoms scores  
3.2 ± 2.2 2.4 ± 2.1 3.1 ± 2.3 2.4 ± 2.1 
Note: Means, standard deviations are presented (Mean ± SD). ADHD = 
attention-deficit/hyperactivity disorder; L/A = left-handed or ambidextrous; R = right-handed. 
 
Table 2: Associations of rs945270 and Sex With Attention-Deficit/Hyperactivity Disorder 
(ADHD) Symptoms  
 
 rs945270 
(effect C-allele) 
Sex 
 
Sex * rs945270 
ADHD symptoms 𝛽 = -0.21, 
p = .005 
𝛽 = -0.77, 
p = 1.12 x 10-12 
𝛽 = 0.049, 
p = .71 
Hyperactivity 𝛽 = -0.126 
p = .005 
𝛽 = -0.361 
p = 1.37 x 10-8 
na 
Inattention  𝛽 = -0.093 
p = .028* 
𝛽 = -0.406 
p = 6.77 x 10-12 
na 
Note: Associations significant affect Bonferroni correction for multiple testing are in bold. Na 
= not assessed. 
* nominally significant association 
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Table 3: Associations of rs945270, Sex on Attention-Deficit/Hyperactivity Disorder (ADHD) 
Symptoms on Putamen Activation Split by Tasks (Monetary Incentive Delay [MID] and Stop 
Signal [SST])   
 SST MID 
 Left 
putamen 
Right  
putamen 
Left putamen Right 
putamen 
rs945270  
(effect C-allele) 
𝛽 = -0.088, 
p = .0030 
𝛽 = -0.089 
p = .0018 
𝛽 = 0.016, 
p = .66 
𝛽 = 0.022, 
p = .38 
Sex 𝛽 = -0.15, 
p = .002 
𝛽 = -0.084, 
p = .035 
𝛽 = -0.10, 
p = 5 x 10-6 
𝛽 = -0.090, 
p = 3.9 x 10-5 
Sex * 
rs945270 
𝛽 = 0.16, 
p = .0080 
𝛽 = 0.087, 
p = .12 
𝛽 = 0.054, 
p = .086 
𝛽 = 0.084, 
p = .0065 
ADHD symptoms 𝛽 = 0.002 
p = .80 
𝛽 =0.003 
p = .76 
𝛽 = -0.009, 
p = .089 
𝛽 = -0.012, 
p = .014* 
Hyperactivity 
𝛽 =0.010 
p = .52 
𝛽 =0.008 
p = .60 
𝛽 = -0.015,  
p = .072 
𝛽 = -0.021,  
p = .013* 
Inattention  
𝛽 =-0.004 
p = .83 
𝛽 =-6.4*10-5 
p = .99 
𝛽 = -0.011,  
p = .25 
𝛽 = -0.016,  
p = .076 
Sex * ADHD 
𝛽 = -0.036, 
p = .06 
𝛽 = -0.02,  
p = .27 
𝛽 = 0.008,  
p = .45 
𝛽 = -0.006,  
p = .55 
Sex * 
Hyperactivity 
𝛽 =-0.033, 
p = .30 
𝛽 = -0.014,  
p = .64 
𝛽 =0.006, 
p = .73  
𝛽 =0.008, 
p = .64 
Sex * 
Inattention 
𝛽 = -0.075,  
p = .028* 
𝛽 = -0.47,  
p = .15 
𝛽 = 0.018,  
p = .34 
𝛽 = -0.01,  
p = .59 
Note: Associations significant affect Bonferroni correction for multiple testing are in bold.  
* nominally significant associations. 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
24  
 
Figures 
Figure 1: A) Relationship between attention-deficit/hyperactivity disorder (ADHD) symptom 
scores and rs945270 in 14-year-old adolescents (error bars denote standard error of the mean 
[SEM]). B) Forest plots of associations between ADHD symptom scores and rs945270 in the 
8 research sites and meta-analysis. Note: The β values obtained at each research site are 
shown as black squares, and the ranges between upper and lower CI95s are shown as the 
black lines. The integrated β as well as its upper and lower CI95s were calculated from the 
meta-analysis by using the inversion of squared standard errors (SEs) as weight, and the 
result is illustrated as the black diamond, where the mean is indicated vertically and the range 
between upper and lower CI95s is indicated horizontally. 
 
Figure 2: Relationship between rs945270 genotypes and blood oxygen level-dependent 
(BOLD) responses within the left (A) and right (B) putamen during successful inhibition of 
motor response in the stop signal (SST) functional magnetic resonance imaging (fMRI) task 
(blue and red represent boys and girls, respectively; error bars denote standard error of the 
mean [SEM]).  
 
Figure 3: Blood oxygen level-dependent (BOLD) responses within the left (A) and right (B) 
putamen during reward anticipation in the monetary incentive delay (MID) functional 
magnetic resonance imaging (fMRI) task stratified by rs945270 genotypes (blue and red 
represent boys and girls, respectively, error bars denote standard error of the mean [SEM]).  
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Supplement 1 
Monetary Incentive Delay Task 
The task consisted of 66 10-second trials. In each trial, participants were presented 
with one of three cue shapes (cue, 250 ms) denoting whether a target (white square) would 
subsequently appear on the left or right side of the screen and whether 0, 2, or 10 points could 
be won in that trial. After a variable delay (4,000-4,500 ms) of fixation on a white crosshair, 
participants were instructed to respond with left/right button-press as soon as the target 
appeared. Feedback on whether and how many points were won during the trial was 
presented for 1,450 ms after the response. Using a tracking algorithm, task difficulty (i.e. 
target duration varied between 100 and 300 ms) was individually adjusted such that each 
participant successfully responded on ~66% of trials. Participants had first completed a 
practice session outside the scanner (~5 minutes), during which they were instructed that for 
each 5 points won they would receive one food snack in the form of small chocolate candies. 
Only successfully “hit” trials were included here. 
Stop Signal Task 
The task was composed of Go trials and Stop trials. During Go trials (83%; 480 trials), 
participants were presented with arrows pointing either to the left or to the right. During these 
trials, participants were instructed to make a button response with their left or right index 
finger corresponding to the direction of the arrow. In the unpredictable Stop trials (17%; 80 
trials), the arrows pointing left or right were followed (on average 300 ms later) by arrows 
pointing upwards; participants were instructed to inhibit their motor responses during these 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
26  
 
trials. A tracking algorithm changes the time interval between Go signal and Stop signal 
onsets according to each participant’s performance on previous trials (average percentage of 
inhibition over previous Stop trials, recalculated after each Stop trial), resulting in 50% 
successful and 50% unsuccessful inhibition trials. The inter-trial interval was 1800ms. 
Stop Signal Reaction Times (SSRT) 
The SST works according to a horse race model, where the stop-signal and go-signal 
develop independently of each other. If the stop-process can be implemented before the 
go-process reaches an ultimate threshold, the response will be successfully inhibited. Stop 
signal reaction times were collected during the SST. However, a problem with the tracking 
algorithm during functional magnetic resonance imaging (fMRI) acquisition of the SST 
resulted in loss of behavioral SSRT data. The problem was that if the participant responded 
prior to a stop stimulus appearing on a stop trial, then that trial was repeated once (a 
maximum of seven such trials; stop-too-early [STE] trials were repeated). This may have 
affected the SSRT as some participants had more STE trials than others. Therefore, for 
participants with more than eight STEs, we calculated the SSRT up to the point of the eighth 
STE. However, for some participants, this occurred early in their run. Therefore, we restricted 
the SSRT analysis only to participants who did not reach their 8th STE before their 300th trial. 
The SSRT can be computed by various methods. In the present study, the SSRT was 
computed by taking the Go RT at the percentile corresponding to the proportion of 
unsuccessfully inhibited Stop trials and subtracting the mean stop signal delay.  
In order to determine that the SSRT-data sample (n=671) is representative of the 
entire sample (n=1,129), we performed analyses in terms of sex, 
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attention-deficit/hyperactivity disorder (ADHD) symptoms, IQ, and socioeconomic status. 
There were 54% girls in the full sample and 55% girls in the SSRT sample; mean ADHD 
symptoms were 2.72 (std.: 2.20) in the full sample and 2.55 (std: 2.11) in the SSRT sample. 
Mean verbal IQ was 112 (std: 14.6) in the full sample and 113 (std: 14.2) in the SSRT 
sample. We also collected information regarding family stresses in our sample through the 
Development and Wellbeing Assessment (DAWBA) questionnaire, which was completed by 
the parent. This questionnaire collects information regarding unemployment, work situation, 
financial difficulties, housing situation, and physical and mental health of the parent to create 
a total score ranging from 1 to 26. In the full sample, this value was 2.69 (std. 2.47) and 2.65 
(std. 2.36) in the SSRT sample. Based on these results, we can only conclude that the SSRT 
sample is representative of the entire tested population. 
Standardization of MRI Protocols Across Sites 
Protocols were developed iteratively, with input from experts from sites with scanners 
from each of the manufacturers involved (GE, Siemens, Philips and Bruker). For structural 
imaging, the well-validated Alzheimer's Disease Neuroimaging Initiative (ADNI) protocols 
were used with only minimal modifications; for other types of scan, a set of desired values 
for parameters such as voxel size were determined by consensus, and a set of dependent 
parameters (e.g. TE, TR) that was possible for all scanners was determined. Phantom scans 
and then in vivo scans were then used to assess signal to noise and contrast to noise ratios at 
each site. More details are given in1. As even minor difference between sites in image quality 
(or other image features that cannot be standardized, such as subtle differences in geometric 
distortion) could still be statistically significant, a variable coding for "site" was included as a 
variable of no interest in all analyses. 
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Supplemental Results 
For the voxel-wise analyses within the whole brain and the putamen, we performed 
both voxel-wise and cluster-wise inference, using random fields method for family wise error 
correction in each contrast, especially setting the uncorrected p-value threshold for cluster 
formation to .001. Only voxels that are significant at both voxel-level and cluster-level are 
illustrated.  
Response Inhibition 
We did not observe significant results from whole-brain voxel-wise association 
analysis with rs945270 in the whole sample, nor in boys or girls when analyzed separately. 
Voxel-wise association analysis within the putamen in boys revealed significant clusters of 
activity in caudal regions of the right putamen that associated with rs945270 genotypes 
during inhibition of motor responses (Table S1).  
Reward Anticipation 
We did not observe significant results from whole-brain voxel-wise association 
analysis with rs945270 in the whole sample, or in boys or girls when analyzed separately. But 
voxel-wise association analysis within the putamen in girls identified significant clusters in 
the right anterior ventral putamen associating with rs945270 (Table S2). 
Table S1: Voxel-Wise Association Analysis With rs945270 in Response Inhibition 
  
Peak T value’s MNI 
coordinates 
Peak T value Peak 
p-value 
Cluster size Cluster 
p-value 
Boys 27, -13, 13 4.36 .003 11 .025 
Note: MNI = Montreal Neurological Institute. 
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Table S2: Voxel-Wise Association Analysis With rs945270 in Reward Anticipation 
  
Peak T value’s 
MNI coordinates  
Peak T value  Peak  
p-value 
Cluster size Cluster  
p-value 
Girls 24, 20, -8 3.76 .035 11 .019 
Note: MNI = Montreal Neurological Institute. 
Figure S1: Multidimensional scaling (MDS) analysis with HapMap populations as reference 
groups, showing that our sample is genetically homogeneous (overlapping with the CEU 
population). Note: ASW = African ancestry in southwest USA; CEU = Utah residents with 
northern and western European ancestry from the Centre d'Etude du Polymorphisme Humain 
(CEPH) collection; CHD = Chinese in metropolitan Denver, Colorado; GIH = Gujarati 
Indians in Houston, Texas; LWK = Luhya in Webuye, Kenya; MEX = Mexican ancestry in 
Los Angeles, California; MKK = Maasai in Kinyawa, Kenya; TSI = Tuscans in Italy; YRI = 
Yoruba in Ibadan, Nigeria. 
Figure S2: Voxel-wise association between rs945270 and blood oxygen level-dependent 
(BOLD) responses within the putamen in boys during successful response inhibition, 
showing clusters of activity in the right posterior putamen (peak voxel: 27, -13, 13). 
Figure S3: Voxel-wise association between rs945270 and blood oxygen level-dependent 
(BOLD) responses within the putamen in girls during reward anticipation, showing clusters 
of activity in the right anterior putamen (peak voxel: 24, 20, -8). 
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